Aditum Bio
Venture capitalOakland · Series A–Series B · 4 people tracked
Also known as ADITUM BIO MANAGEMENT COMPANY, LLC
Investment thesis
Aditum Bio positions itself as a new model of biotech venture capital aimed at accelerating the translation of scientific discoveries into new medicines that improve patients' lives. The firm focuses on identifying promising science and moving it quickly toward clinical development.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from the firm's website & public directories
What they invest in
from 5 of 7 portfolio companiesBiotech ×5Medical Devices ×5Digital Health ×3Healthtech ×2
HQs:United States×4
Investments · 7 tracked
founders shown can be your intro pathCoastline Bio is a biopharmaceutical company developing novel medicines for immunological skin diseases, with an initial focus on atopic dermatitis.
BiotechHealthtechMedical DevicesOakland, US
Oakland, US
Board seatJoseph JimenezJoshua Gertsman· per SEC Form D · $77M raise · filed Nov 2025
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections.
BiotechDigital HealthMedical Devices
Donald Ganem(Executive Officer, Director)Joseph Jimenez(Director)Benjamine Liu(Director)Ilan Zipkin(Director)
Board seatJoseph Jimenez· per SEC Form D
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source.
BiotechDigital HealthMedical DevicesOakland, US
Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention.
BiotechDigital HealthMedical Devices
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion.
BiotechHealthtechMedical DevicesLexington, US
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Aditum Bio invest at?
- Aditum Bio invests at the Series A, Series B stages.
- What sectors does Aditum Bio focus on?
- Aditum Bio focuses on AI & Machine Learning, Biotech.
- Where is Aditum Bio located?
- Aditum Bio is headquartered in Oakland, US.
Images
Co-investors · 1
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Firms observed investing alongside Aditum Bio, from public investor directories. Shared companies are the overlap with Aditum Bio's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Bessemer Venture Partners is a venture capital firm that partners with entrepreneurs from early stages through every stage of growth, publishing investment roadmaps across multiple technology sectors.